Industrial Profile

The biotech business is a market-tested industry. For more than 20 years investment in the biotech sector has continued at a very significant growth rate. Biotech investment in frontier sciences dealing with genomics, proteomics, biochips, bioinformatics, new drug discoveries, high throughput screening, tissue engineering, and agrogenomics has become even more prominent in the post-genome era. Investment return of the biotech sector has outperformed all other industries since the second half of 1999, and has also outperformed all other market indices. In fact, the biotech sector, which is closely related to the pharmaceutical sector, has been the safe haven for investors in times of economic uncertainty and in the chaotic environment of e-businesses and the IT industry.

The deciphering of human genome as well as genomes from other biological systems will reveal a significant volume of new information on the living systems that human being has never engaged. This makes the biotech industry a business sector that deals with a brand new set of knowledge management issues. Thus, in today's knowledge economy, the biotech industry has the most potential for business, and therefore profits, compared to other sectors.

President Life Sciences has recognized these trends of economic and technological development and has designed strategic approaches to exploiting new opportunities in the biotech industry, utilizing the combined resources of the Tainan Business Group for its business development. PLS also recognizes the importance of wealth and experience collectively acquired by Taiwan's high-tech industry in the past 15 years. Such wealth and experience are essential for and can provide critical supports to developing a significant biotech industry in Taiwan within the context of convergence of biotech and high-tech. Furthermore, PLS is committed to utilize its extensive experience in biotech commercialization for developing a prominent biotech business in the greater China region as well as in Asia.